Dominog effect: drugs with an uncertain pricing future in Germany
This article was originally published in Scrip
Executive Summary
News that gliptins already on the market are to undergo the early benefit assessment in Germany should be sounding warning bells for dozens of recently approved drugs in Germany – and for their competitors. Retrospective action could mean not only lower prices, but potentially the strategic withdrawal of drugs from the German market so that prices in Germany do not erode prices elsewhere in Europe, say industry commentators.